Embria Studies FDA Expectations Before Successful EpiCor NDI
This article was originally published in The Tan Sheet
Executive Summary
FDA’s formal acknowledgment of Embria’s NDI notification for EpiCor comes after the firm called FDA early in the process to discuss the pending notification and worked to understand the agency’s expectations fully. Kevin Boot, Embria’s regulatory counsel, recommends simple notifications that are “readable by everyone.”